BCL2 and diffuse large B-cell lymphoma: At present, preclinical experiments have proved that ixazomib has not only anti-tumor activity in DLBCL cell lines, but also inhibitory activity in DLBCL cell lines that have translocation of MYC and BCL2, and its IC50 value is 40-200 nm.